



Programme for the NMPN Spring Meeting 2019

Date: The 6th of March 2019, 10:00 – 17:10

Venue: Clarion Hotel Copenhagen Airport, Denmark

- 10:00 – 10:30: Registration and light morning meal
- 10:30 – 10:35: Welcome by chairman Christen Lykkegaard Andersen and secretary Trine Alma Knudsen
- 10:35 – 11:00: Myeloproliferative neoplasms and thromboembolic disease - just add aspirin? *Christen Lykkegaard Andersen, MD, DMSc, PhD, Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Denmark*
- 11:00 – 11:15: Prevalence of calretikulin and JAK2V617F mutations in the general population, *Sabrina Cordua, MD, PhD, Department of Haematology, Zealand University Hospital, Roskilde, Denmark*
- 11:15 – 12:15: Keynote presentation
Molecular insights into JAK2 regulation in MPNs, *Olli Silvennoinen, professor, MD, PhD, Director of Institute of Biotechnology, Helsinki, Finland*
- 12:15 – 13:15: Lunch
- 13:15 – 14:15: Keynote presentation
Interferon in the treatment of MPNs, *Heinz Gisslinger, professor, MD, Medical University of Vienna, Austria*
- 14:15 – 14:45: The DALIAH trial, *Trine Alma Knudsen, MD, Department of Haematology, Zealand University Hospital, Roskilde*
- 14:45 – 15:15: Ruxolitinib and pegylated interferon-alpha2 combination therapy, *Anders Lindholm Sørensen, MD, Institute for Inflammation Research, Rigshospitalet, Copenhagen University Hospital, Denmark*
- 15:15 – 15:45: Afternoon Break

- 15:45 – 16:30: Therapeutic cancer vaccines in MPN – from bench to bedside, *Morten Holmström, MD, PhD, National Center for Cancer Immunotherapy, Copenhagen University Hospital, Herlev, Denmark and Jacob Grauslund, MD, National Center for Cancer Immunotherapy, Copenhagen University Hospital, Herlev, Denmark*
- 16:30 – 17:00: Eosinophilia, *Christen Lykkegaard Andersen, MD, DMSc, PhD, Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Denmark*
- 17:00 – 17:10: Rounding off the day by chairman Christen Andersen and secretary Trine Alma Knudsen
- 18:00 – 22:00: 3-course dinner

The meeting is sponsored by Novartis and AOP Orphan Pharmaceuticals.

